Medicure Inc (TSXV:MPH) is a pharmaceutical company focused on the development and commercialization of cardiovascular medicines for the U.S. market. Our vision is to become a leading pharmaceutical company within the U.S., offering a growing portfolio of products that improve patients' lives. We take pride in providing safe, efficacious, and cost-effective cardiovascular medicines that benefit both patients and healthcare providers.

Currently, we focus on the marketing & distribution of:
1. AGGRASTAT® (tirofiban hydrochloride) injections, a hospital-based product used in the cardiac catheterization lab. AGGRASTAT is the #1 used medication of its class in the U.S.
2. ZYPITAMAG® (pitavastatin) tablets, the latest statin medication approved by the FDA in 2017.

In 2020, we acquired Marley Drug, a local pharmacy in North Carolina. Our acquisition of Marley Drug increases patient access to medications, including Medicure's primary care drug, ZYPITAMAG® (Pitavastatin) tablets.

At Medicure, our passion drives us to innovate and find solutions to better support patients.

For more information, please see our website at www.medicure.com and follow us on Twitter at @MedicureInc. For guidelines on engaging with Medicure on social media, please visit bit.ly/MedicureSocial

Pharmaceutical

Medicure

Medicure's headquarters in Winnipeg, Canada

Description

People (10)

Jobs (0)

Other offices